Results 21 to 30 of about 5,941 (192)

การศึกษาการสั่งใช้ยาRabeprazoleชนิดรับประทานในผู้ป่วยนอก ที่เข้ารับการรักษาที่โรงพยาบาลพระนครศรีอยุธยา A Study of Oral Rabeprazole Prescription for Outpatient Treatment at Phra Nakhon Si Ayutthaya Hospital [PDF]

, 2023
บทคัดย่อ   วัตถุประสงค์: เพื่อศึกษาการสั่งใช้ยา rabeprazole ชนิดรับประทานทั้งข้อบ่งใช้และขนาดใช้เปรียเทียบกับที่ขึ้นทะเบียนไว้กับสำนักงานคณะกรรมการอาหารและยาของประเทศสหรัฐอเมริกา (US FDA) หรือตามแนวเวชปฏิบัติของสมาคมแพทย์ระบบทางเดินอาหารแห่งประเทศไทย ...
Yimprasert, Dhanaphat, Peepratoom, Natee, Bussaparoek, Woranut, Nikornpase, Kanokphan   +3 more
core  

Quality Control and Standardization of Rabeprazole Tablets: Quality Control and Standardization of Rabeprazole Tablets

, 2020
Rabeprazole sodium is a new stable pharmaceutical composition developed by us in tablet form, consisting of rabeprazole sodium as active ingredient, excipients, a separating layer and enteric coating.
Anisimov, Alexander, Egorova, Svetlana, Chuvashova, Dinara, Garmonov, Sergey   +3 more
core   +1 more source

Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial

Frontiers in Medicine, 2021
Background: Proton pump inhibitors (PPIs) are validated gastric acid suppressors and have been widely used to treat patients with active duodenal ulcers.
Xu Shu, Zhenhua Zhu, Yu Fu, Zhenyu Zhang, Jiangbin Wang, Xing Li, Shuixiang He, Huizhen Fan, Side Liu, Guoxin Zhang, Jianhua Tang, Caibin Huang, Qin Du, Xiaoyan Wang, Baohong Xu, Yiqi Du, Qikui Chen, Bangmao Wang, Ying Chen, Xianghui Duan, Yong Xie, Lijuan Huo, Xiaohua Hou, Nonghua Lu   +23 more
doaj   +1 more source

Comparison of the effectiveness of rabeprazole original and generic products in the monotherapy of gastroesophageal reflux disease

Терапевтический архив, 2023
Aim. To compare the effectiveness of rabeprazole original and generic products in the treatment of gastroesophageal reflux disease (GERD) using impedance-pH monitoring. Materials and methods.
Oksana V. Krapivnaia
doaj   +1 more source

Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.: PK/PD interaction between rabeprazole and clopidogrel [PDF]

, 2013
International audienceBACKGROUND: Several studies have suggested that proton-pump inhibitors (PPIs), mostly omeprazole, interact with clopidogrel efficacy by inhibiting the formation of its active metabolite via CYP2C19 inhibition.
Gaussem, Pascale, Steichen, Olivier, Funck-Brentano, Christian, Szymezak, Jean, Ducint, Dominique, Azizi, Michel, Molimard, Mathieu, Remones, Véronique   +7 more
core   +1 more source

The Effect of Rabeprazole on Injection Sclerotherapy Complications after First Attack Bleeding Esophageal Varices [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2014
Background and study aim : Endoscopic variceal sclerotherapy (EVS) effectively controls bleeding esophageal varices (OV), however it has some adverse effects including sclerosant ulcers, chest pain, dysphagia and odynophagia. Gastric acid plays a central
Ashraf Metwally, Ahmad Sherbini, Eman El-Shami   +2 more
doaj   +1 more source

In vitro effects of rabeprazole on human pylorus tone [PDF]

, 2015
WOS: 000352750400009PubMed ID: 25843074Background/Aims It has been reported that proton pump inhibitors induce relaxation in different types of smooth muscles.
Polat, Erdal, Uzun, Orhan, Dağdelen, Meltem, Yaşar, Necdet Fatih, Yol, Sinan, Duman, Mustafa, Akyüz, Cebrail, Günal, Mehmet Yalçın, Peker, Kıvanç Derya   +8 more
core   +1 more source

Rabeprazole

Reactions Weekly, 2022
Rabeprazole is a proton pump inhibitor that suppresses gastric acid production in the stomach. Available under different brand name products as well as in a variety of combination products, rabeprazole has several medical uses concerning the management of problems of pathological gastric acid.
  +4 more sources

CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.

PLoS ONE, 2020
Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy.
Hiroya Matsuoka, Koji Ando, Emma J Swayze, Elizabeth C Unan, Joseph Mathew, Quingjiang Hu, Yasuo Tsuda, Yuichiro Nakashima, Hiroshi Saeki, Eiji Oki, Ajit K Bharti, Masaki Mori   +11 more
doaj   +1 more source

Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2020
Aim. Presentation of the Forum “Deprescribing and optimal selection of proton pump inhibitors” held in Moscow on 29 September 2020 during the 26th United Russian Gastroenterology Week.Key points.
V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, A. A. Sheptulin, V. I. Simanenkov, T. L. Lapina, I. B. Khlynov, N. N. Dekhnich, O. D. Lopina, O. P. Alekseeva, N. V. Korochanskaya, M. F. Osipenko, P. V. Pavlov, S. S. Pirogov, G. N. Tarasova, Yu. P. Uspenskiy, D. N. Andreev, D. E. Rumyantseva   +17 more
doaj   +1 more source